Class of 2025
For vital contributions to pancreas cancer research, including the development of patient-derived xenograft models and new treatments such as nab-paclitaxel, and for instrumental efforts in pioneering innovative clinical trial designs and advancing the clinical development of more than 30 new anticancer agents.
*Full-length biography in development
[Institutional affiliations listed for Fellows reflect those held at the time of their induction into the AACR Academy.]